From Plan to Impact report launch
The report launch of From Plan to Impact IV: Progress towards targets of the WHO Global action plan on dementia will take place virtually on 26 May.
News & events
News, conferences, events, blogs and updates from across the field of dementia and the work of Alzheimer's Disease International.
Featured news and events
ADI Council Meeting of 2021
The ADI Council met on 30 March 2021 to discuss ADI's activities over 2020, new membership applications and more.
New blood test research for diagnosis of Alzheimer’s disease shows promising results
A new study in the Lancet Neurology has shown that blood phosphorylated tau 181 may be a promising biomarker for Alzheimer’s disease.
ADI welcomes new Associations and Board members
ADI welcomes three new Alzheimer associations, as well as new members to the ADI board.
ADI releases a position paper on COVID-19 and dementia
ADI releases a position paper on the difficult decisions people with dementia, their families and carers are having to make around hospital admission and triage during COVID-19.
COVID-19: Sharing experience and advice from ADI’s member association in China
Professor Huali Wang of Alzheimer's Disease Chinese (ADC) explains how China has addressed the specific challenges of people living with dementia during COVID-19.
Global Perspective for February 2020
ADI's Global Perspective for February 2020 now available.
Roche to end DIAN-TU-001 study for rare Autosomnal dominant Alzheimer’s disease
Roche announces end of DIAN-TU-001 study after it failed to meets its primary endpoint in people who are affected by early onset Autosomal dominant Alzheimer’s disease.
China approves first drug for mild to moderate Alzheimer’s in 17 years
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
Biogen and Eisai announce plans to file for market approval of Alzheimer’s drug
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.